Zhejiang AngLiKang Pharmaceutical CO.,LTD.
SZSE:002940.SZ
17.9 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 1,625.867 | 1,568.437 | 1,380.378 | 1,289.647 | 1,396.194 | 1,255.048 | 873.154 | 671.581 | 773.794 | 681.508 |
Cost of Revenue
| 900.509 | 670.548 | 487.759 | 317.373 | 375.321 | 378.345 | 409.552 | 454.885 | 594.83 | 523.764 |
Gross Profit
| 725.358 | 897.889 | 892.618 | 972.274 | 1,020.873 | 876.703 | 463.603 | 216.696 | 178.964 | 157.744 |
Gross Profit Ratio
| 0.446 | 0.572 | 0.647 | 0.754 | 0.731 | 0.699 | 0.531 | 0.323 | 0.231 | 0.231 |
Reseach & Development Expenses
| 143.369 | 112.622 | 52.553 | 43.877 | 37.347 | 46.209 | 40.965 | 46.836 | 40.626 | 36.629 |
General & Administrative Expenses
| 57.964 | 17.295 | 36.564 | 33.35 | 45.543 | 31.591 | 28.587 | 10.851 | 12.112 | 67.498 |
Selling & Marketing Expenses
| 293.019 | 559.078 | 609.81 | 690.89 | 765.204 | 646.752 | 231.573 | 27.93 | 21.954 | 23.387 |
SG&A
| 350.983 | 576.373 | 646.374 | 724.24 | 810.748 | 678.343 | 260.159 | 38.781 | 34.066 | 90.885 |
Other Expenses
| -4.482 | 63.833 | 32.037 | 0.214 | 22.034 | 6.074 | -0.179 | 5.84 | 7.094 | 6.907 |
Operating Expenses
| 509.021 | 752.828 | 730.964 | 768.331 | 870.129 | 756.447 | 328.177 | 110.778 | 98.311 | 94.39 |
Operating Income
| 211.681 | 148.558 | 174.171 | 211.681 | 155.103 | 131.239 | 123.716 | 89.326 | 61.032 | 49.721 |
Operating Income Ratio
| 0.13 | 0.095 | 0.126 | 0.164 | 0.111 | 0.105 | 0.142 | 0.133 | 0.079 | 0.073 |
Total Other Income Expenses Net
| -4.482 | -1.613 | -1.524 | -0.936 | -1.413 | 17.057 | -11.888 | -10.752 | -12.527 | -13.185 |
Income Before Tax
| 207.2 | 146.945 | 172.647 | 210.745 | 153.69 | 137.313 | 123.537 | 95.166 | 68.126 | 50.17 |
Income Before Tax Ratio
| 0.127 | 0.094 | 0.125 | 0.163 | 0.11 | 0.109 | 0.141 | 0.142 | 0.088 | 0.074 |
Income Tax Expense
| 24.135 | 14.957 | 31.325 | 29.444 | 27.232 | 15.644 | 18.104 | 14.234 | 10.028 | 8.664 |
Net Income
| 138.372 | 127.296 | 119.844 | 163.719 | 112.27 | 108.697 | 101.085 | 82.188 | 64.027 | 50.128 |
Net Income Ratio
| 0.085 | 0.081 | 0.087 | 0.127 | 0.08 | 0.087 | 0.116 | 0.122 | 0.083 | 0.074 |
EPS
| 0.69 | 0.64 | 0.61 | 0.86 | 0.59 | 0.73 | 0.71 | 0.58 | 0.45 | 0.35 |
EPS Diluted
| 0.69 | 0.64 | 0.61 | 0.86 | 0.59 | 0.73 | 0.71 | 0.58 | 0.45 | 0.35 |
EBITDA
| 312.758 | 219.992 | 222.278 | 259.392 | 193.683 | 169.14 | 167.468 | 146.054 | 128.282 | 106.163 |
EBITDA Ratio
| 0.192 | 0.14 | 0.161 | 0.201 | 0.139 | 0.135 | 0.192 | 0.217 | 0.166 | 0.156 |